Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1584MR)

This product GTTS-WQ1584MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1584MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6373MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ813MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ2843MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ11460MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ1939MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ14299MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ11731MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ5375MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW